E. Fumero

Risk of Selecting De Novo Drug-Resistance Mutations during Structured Treatment Interruptions in Patients with Chronic HIV Infection

Mireia Arnedo‐Valero, Felipe García, T. Guila et al. · Clinical Infectious Diseases · 2005 · 48 citations · Full text

Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)

Beatriz Hernández‐Novoa, Antonio Moreno, Maria Jesús Pérez‐Elías et al. · Journal of Antimicrobial Chemotherapy · 2013 · 23 citations · Full text

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: <i>post hoc</i> analysis through 64 weeks from reSURFACE 1 trial

Richard B. Warren, J.M. Carrascosa, E. Fumero et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 23 citations · Full text

Immunosuppressive drugs as an adjuvant to HIV treatment

E. Fumero · Journal of Antimicrobial Chemotherapy · 2004 · 14 citations · Full text

Neurovirology, Productive Hiv Infection, Human Retrovirus +13

Long-term Clinical Follow-up, without Antiretroviral Therapy, of Patients with Chronic HIV-1 Infection with Good Virological Response to Structured Treatment Interruption

Éric Florence, Felipe García, Montserrat Plana et al. · Clinical Infectious Diseases · 2004 · 11 citations · Full text

Immunology, Human Immunodeficiency Virus, Immunotherapy +17